Desmoid tumor
MONDO:0007608A desmoid tumor (DT) is a benign, locally invasive soft tissue tumor associated with a high recurrence rate but with no metastatic potential.
Also known as: aggressive fibromatosis, deep fibromatosis, deep fibromatosis/desmoid tumor, deep fibromatosis/desmoid tumour, desmoid fibromatosis, desmoid tumor, desmoid type fibromatosis, desmoid-type fibromatosis
1471 clinical trials for this condition and its sub-types, 36 tagged with Desmoid tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Desmoid tumor
-
New drug tested to protect fertility in women with rare tumors
Disease control Recruiting nowThis study tests the drug nirogacestat in 50 premenopausal women with desmoid tumors (a type of non-cancerous but aggressive growth). The main goal is to see if the drug affects ovarian function, such as menstrual periods and hormone levels. Participants take nirogacestat orally,…
Phase 4 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Freeze and pill combo takes on rare tumors
Disease control Recruiting nowThis study tests a two-step approach for desmoid tumors, which are non-cancerous but can be painful and grow. First, patients take a daily pill called nirogacestat for three months. Then, one tumor is frozen with a special needle (cryoablation). The goal is to see if this combina…
Phase 2 • Sponsor: Nam Bui • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for young cancer patients: experimental drug targets recurrent tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …
Phase 1/2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Phase 1/2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug trial aims to shrink desmoid tumors
Disease control Recruiting nowThis study tests an investigational drug called nirogacestat in about 40 adults with desmoid tumors (a type of non-cancerous growth). The main goal is to check the drug's safety and side effects. Researchers will also see how the tumor responds to treatment.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare tumor patients: chemo delivered directly to desmoid growths
Disease control Recruiting nowThis study is for people with symptomatic desmoid tumors that are growing and cannot be treated with surgery or freezing. Researchers are testing a procedure that delivers chemotherapy (doxorubicin) directly into the tumor through a small tube in an artery, aiming to shrink the t…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Last-Resort drug access for rare tumor patients
Disease control Expanded accessThis program provides nirogacestat to people with serious desmoid tumors or NOTCH gene mutation tumors who have no other treatment options and cannot join a clinical trial. Each case is reviewed individually by the company, ethics board, and health authorities. The goal is to con…
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug ES014 targets desmoid tumors in Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial is testing a drug called ES014 in 50 adults with desmoid tumors, a type of non-cancerous but often painful growth. The drug is given as an IV infusion every two weeks. The main goal is to see if the tumors shrink, while also checking safety and quality of life.
Phase 2 • Sponsor: Elpiscience (Suzhou) Biopharma, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New pill shows promise in slowing rare Cancer's growth
Disease control Recruiting nowThis study tests an experimental oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow cancer growth for at least 3 months. The drug targ…
Phase 2 • Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Sound waves vs. tumors: new ultrasound treatment tested for sarcoma
Disease control Recruiting nowThis pilot study is testing whether high-intensity focused ultrasound (HIFU) can safely destroy soft tissue sarcoma and small desmoid tumors without surgery. About 10-16 adults with these tumors will receive a single outpatient treatment using a CE-approved device. The goal is to…
Sponsor: Oxford University Hospitals NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Freeze or chemo? new trial tests a less harsh option for desmoid tumors
Disease control Recruiting nowThis study tests whether freezing desmoid tumors with a needle (cryoablation) works better than standard chemotherapy for people whose tumors have grown after a period of watchful waiting. About 150 participants will be randomly assigned to one of the two treatments. If the tumor…
Sponsor: University Hospital, Strasbourg, France • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
No-Chemo embolization tackles rare desmoid tumors
Disease control Recruiting nowThis study looks at whether blocking the blood supply to desmoid tumors (using tiny particles injected into the arteries) can shrink the tumor and reduce pain without using chemotherapy. It will follow 20 people aged 12 and older who have painful, growing desmoid tumors that cann…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 26, 2026 16:10 UTC
-
Massive childhood cancer registry launches to unlock better treatments
Knowledge-focused Recruiting nowThis study is a large registry that collects health information and leftover tumor or blood samples from up to 75,000 children and young adults with cancer. The goal is to track outcomes and gather data to help doctors find better ways to treat and care for these patients over ti…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Desmoid tumor study: just watching may be enough
Knowledge-focused Recruiting nowThis study follows 100 people with desmoid-type fibromatosis, a rare tumor, for 12 months without giving any treatment. The goal is to see how often the tumors stay stable or shrink on their own. Participants get regular MRI or CT scans to track changes. The results could help do…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New imaging method may spot tumor growth earlier after freezing treatment
Knowledge-focused Recruiting nowThis study looks at whether a detailed MRI analysis called radiomics can predict if a desmoid tumor will grow back after cryoablation (freezing treatment) better than standard methods. Researchers will follow 21 patients treated at one hospital to compare radiomics with usual siz…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Immune clues could predict desmoid tumor behavior
Knowledge-focused Recruiting nowThis study looks at the immune system of 200 people with desmoid tumors, either under observation or receiving treatment. Researchers will analyze blood and tumor samples to find markers that may predict whether the tumor shrinks, stays stable, or grows. The goal is to better und…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC